[Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produkte
April 24, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Konzernverkäufe stiegen um 2%1 zu konstanten Wechselkursen (CER; -6% in CHF) dank starkem Wachstum der jüngeren Medikamente und Diagnostika; ohne COVID-19-Produkte nahmen die Konzernverkäufe um 7% zu;...
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
April 24, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going...
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
April 17, 2024 02:00 ET
|
F. Hoffmann-La Roche Ltd
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%)...
Roche’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions
October 11, 2023 02:00 ET
|
F. Hoffmann-La Roche Ltd
Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on OCREVUS levels in the blood over 12 weeks OCREVUS subcutaneous injection was comparable to...
Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD
October 02, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Late-breaking results from Phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in multiple sclerosis (MS) will be presented10-year OCREVUS...
La 9e édition du Comiccon de Québec en octobre : une célébration de la culture populaire au Centre des congrès
September 20, 2023 11:36 ET
|
Comiccon de Québec
QUÉBEC, 20 sept. 2023 (GLOBE NEWSWIRE) -- Le Centre de congrès de Québec accueillera la neuvième édition du Comiccon de Québec les 7 et 8 octobre 2023. Des milliers d’adeptes des comic books,...
[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche verzeichnet starkes Wachstum im Basisgeschäft beider Divisionen; Konzernverkäufe und -gewinn widerspiegeln rückläufige Nachfrage nach COVID-19-Produkten
July 27, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Basel, 27. Juli 2023 Verkäufe der Roche-Gruppe ohne COVID-19-Produkte steigen deutlich um 8%1 zu konstanten Wechselkursen (CER) Durch die erwartungsgemäss rückläufige Nachfrage nach...
[Annonce événementielle au sens de l’art. 53 RC] Roche fait état d’une forte croissance de son activité de base dans ses deux divisions ; les ventes et le bénéfice du groupe reflètent la baisse des ventes de produits liés au COVID-19
July 27, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Bâle, le 27 juillet 2023 Sans les produits liés au COVID-19, le chiffre d’affaires consolidé a fortement augmenté de 8 %1 à taux de change constants (TCC) Conformément à la baisse de la demande...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions’ base business; Group sales and profit reflect declining demand for COVID-19 products
July 27, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Basel, 27 July 2023 Excluding COVID-19 products, Group sales increase strongly by 8%1 at constant exchange rates (CER) In line with the expected declining demand for COVID-19 products, Group sales...
Positive Phase III results for Roche’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
July 13, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Phase III OCARINA II trial met primary and secondary endpoints OCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS...